SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders and oncology, will present data on cenobamate at the American Epilepsy Society (AES) Annual Meeting, to be held December 1-5, 2023, in Orlando, Florida.
“We recognize that the path to seizure management can be challenging for those living with epilepsy,” said Louis Ferrari, BS, RPh, MBA, Vice President of Medical Affairs at SK Life Science. “Our participation at AES, from our symposium to our data, will offer valuable information to providers so they have updated information to address their patients’ needs. This includes insights on potential solutions for challenges like medication delivery and administration.”
Symposium will discuss unmet need for seizure freedom in patients with epilepsy
SK Life Science will host a symposium titled the ‘Impact of Continued Seizures and Strategies for Seizure Reduction/Freedom’ which will be held on Saturday, December 2 at 6:00 p.m. ET, in the Plaza Ballroom H of the West Concourse, Orange County Convention Center.
The symposium will discuss currently available strategies for reducing and achieving seizure freedom, the need to better understand unmet needs for achieving seizure freedom, the impact of continued seizures on patients, evidence-based treatment adjustments before patients consider surgery, and the various treatment options available to support patients in their epilepsy journey.